Abstract

Obesity is ubiquitous, affecting millions of people all over the world. Its prevalence is increasing day by day in all age groups, ranging from children to adolescents to adults. It has a significant impact on the overall quality of life. Obesity has a strong relationship with various chronic conditions, including type 2 diabetes mellitus. The risk of developing diabetic mellitus considerably increases in obese individuals. Similarly, obesity in diabetic patients increases their probability of developing serious complications. Moreover, the optimal approach to managing diabetes mellitus (type 2) and obesity should be carried out by means of sustained weight loss and glycemic control. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to be a revolutionary class of medications with noteworthy weight-loss benefits in addition to their ability to lower blood sugar levels. These remarkable benefits are mentioned in detail in several different clinical trials. Additionally, diverse mechanisms have also been demonstrated comprehensively via which SGLT-2 inhibitors put forth their function of weight loss. FDA-approved SGLT2 inhibitors show a unique mechanism of action by inhibiting the reabsorption of glucose in the renal proximal tubule. By excreting glucose in the urine and by visceral fat lipolysis, these drugs provide a new avenue for weight reduction. SGLT2 inhibitors are now fundamental parts of weight-loss regimens in patients with type 2 diabetes, going beyond their original role as anti-diabetic medications. This article attempts to review the up-to-date literature on the effectiveness of this particular contemporary function of SGLT2 inhibitors.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.